共病纤维肌痛损害银屑病关节炎患者生物制剂疗效
该真实世界研究纳入238例起始首个生物制剂的银屑病关节炎患者,其中58例合并纤维肌痛。合并纤维肌痛者药物生存率显著更低(50% vs 74%),缓解/低疾病活动度和MDA达标率在3、6、12、24个月均显著更低。无纤维肌痛和正常体重是停药负预测因子,无纤维肌痛和男性是持续MDA正预测因子。
要点
- 合并纤维肌痛使生物制剂药物生存率从74%降至50%。
- 合并纤维肌痛者缓解率极低,3个月仅3.4%,6个月为0%。
- 无纤维肌痛和正常体重与较低停药风险相关。
核心结论
- 合并纤维肌痛、女性性别和肥胖似乎是银屑病关节炎最差的负预后因素组合。
研究设计与样本
- 真实世界研究,纳入2010年至2017年起始首个生物制剂的银屑病关节炎患者238例,其中58例合并纤维肌痛。
主要发现
- 合并纤维肌痛者药物生存率显著低于无纤维肌痛者(50%,平均32个月 vs 74%,平均42个月,P=0.0001)。
- 合并纤维肌痛者在3、6、12和24个月时缓解/低疾病活动度和MDA达标率均显著更低(P<0.001)。
- 合并纤维肌痛者3个月缓解率为3.4%,6个月为0%。
- 停药负预测因子为无纤维肌痛(HR 0.51)和正常体重(HR 0.29)。
- 持续MDA正预测因子为无纤维肌痛(HR 2.54)和男性(HR 1.58)。
临床怎么用
- 对银屑病关节炎患者起始生物制剂前应评估纤维肌痛共病,以预判疗效不佳风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of FM on the clinical outcomes of biologics in patients with PsA in real life. METHODS: FM was diagnosed according to current criteria among PsA patients starting a first biologic drug from 2010 through 2017. At each visit, disease activity of PsA (DAPSA), minimal disease activity (MDA), HAQ, rate of patients achieving DAPSA-based low disease activity (LDA) or remission, and MDA were evaluated. Lost patients or those not achieving the target were imputed as non-responders. The drug survival was evaluated by Kaplan-Meyer analysis. Estimated hazard ratios (HRs) of discontinuing therapy or achieving MDA were assessed by multivariate regression models. RESULTS: A total of 238 patients, of whom 58 had also FM, started a first biologic drug. Compared with no-FM PsA, FM PsA patients were more frequently female (P = 0.0001) with polyarticular subset (P = 0.0001), and with higher mean BMI (P = 0.006). Drug survival was significantly lower in FM PsA (50%, mean 32 months) than in no-FM PsA (74%, mean 42 months, P = 0.0001). Rates of remission/LDA and MDA were significantly lower in FM PsA at 3, 6, 12 and 24 months (P < 0.001). Remission in FM PsA was negligible (3.4% and 0% at 3 and 6 months, respectively). Negative predictors of drug discontinuation were no FM (HR 0.51) and normal weight (HR 0.29), while no FM (HR 2.54) and male sex (HR 1.58) were positive predictors of long-standing MDA. CONCLUSIONS: Comorbid FM, along with female gender and obesity seem to be the worst combination of negative prognostic factors in PsA.
引用
- Iannone F, Nivuori M, Fornaro M, et al. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology (Oxford). 2020. PMID: 31652315. doi:10.1093/rheumatology/kez505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。